Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC).

T. Mok; D. R. Spigel; K. Park; M. A. Socinski; S. Y. Tung; D. Kim; G. Borzillo; H. Zhang; J. P. O'Connell; P. A. Janne

doi:10.1200/jco.2010.28.15_suppl.7537

Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7537 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7537-7537 ◽

Cited By ~ 7

Author(s):

T. Mok ◽

D. R. Spigel ◽

K. Park ◽

M. A. Socinski ◽

S. Y. Tung ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Efficacy And Safety ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Do We Really Need Another Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in First-Line Treatment for Patients With Non–Small-Cell Lung Cancer andEGFRMutations?

Journal of Clinical Oncology ◽

10.1200/jco.2013.52.8794 ◽

2014 ◽

Vol 32 (8) ◽

pp. 859-863 ◽

Cited By ~ 2

Author(s):

Eva R. Haspinger ◽

Marina Chiara Garassino ◽

Valter Torri ◽

Michela Cinquini ◽

Filippo De Braud ◽

...

Keyword(s):

Lung Cancer ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Pharmacoeconomic analysis of Giotrif® (afatinib) as first-line treatment of metastatic non-small cell lung cancer with Del19 mutation of epidermal growth factor receptor (EGFR) gene

Malignant tumours ◽

10.18027/2224-5057-2015-4-35-47 ◽

2015 ◽

pp. 35 ◽

Cited By ~ 1

Author(s):

Vera Andreevna Gorbunova ◽

Sergey Vladimirovich Orlov ◽

Sergey Kensarinovich Zyryanov ◽

Dmitriy Yuryevich Belousov

Keyword(s):

Lung Cancer ◽

Pharmacoeconomic Analysis ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Egfr Gene ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Overall survival (OS) of real-world patients with stage IIIb/IV non-small cell lung cancer (NSCLC) initiating epidermal growth factor receptor (EGFR) targeted tyrosine kinase inhibitors (TKI) as first-line treatment in England

Lung Cancer ◽

10.1016/s0169-5002(19)30138-2 ◽

2019 ◽

Vol 127 ◽

pp. S40

Author(s):

U. Rigney ◽

K. Lock ◽

C. Chen ◽

C. Escriu

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Kinase Inhibitors ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Rationale and design of a phase II trial of osimertinib as first-line treatment for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (SPIRAL-0 study)

Translational Lung Cancer Research ◽

10.21037/tlcr.2019.11.19 ◽

2019 ◽

Vol 8 (6) ◽

pp. 1086-1090

Author(s):

Yusuke Chihara ◽

Tadaaki Yamada ◽

Junji Uchino ◽

Nobuyo Tamiya ◽

Yoshiko Kaneko ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.7012 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 7012-7012 ◽

Cited By ~ 43

Author(s):

R. Rosell ◽

C. Daniel ◽

R. Ramlau ◽

A. Szczesna ◽

M. Constenla ◽

...

Keyword(s):

Lung Cancer ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Randomized Phase Ii ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.7012 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 7012-7012 ◽

Cited By ~ 9

Author(s):

R. Rosell ◽

C. Daniel ◽

R. Ramlau ◽

A. Szczesna ◽

M. Constenla ◽

...

Keyword(s):

Lung Cancer ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Randomized Phase Ii ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

9123 POSTER Final Results of a Phase II Study of Gefitinib as First-line Treatment in Elderly Epidermal Growth Factor Receptor-mutated Patients With Advanced Non-small Cell Lung Cancer – Gefitinib for Elderly Patients With Lung Adenocarcinoma

European Journal of Cancer ◽

10.1016/s0959-8049(11)72435-2 ◽

2011 ◽

Vol 47 ◽

pp. S630

Author(s):

K. Asami ◽

T. Koizumi ◽

K. Hirai ◽

S. Ameshima ◽

A. Tsukadaira ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Gefitinib Plus Pemetrexed As First-Line Treatment in Patients With Nonsquamous Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

Journal of Clinical Oncology ◽

10.1200/jco.2016.70.2472 ◽

2017 ◽

Vol 35 (6) ◽

pp. 692-692 ◽

Cited By ~ 3

Author(s):

Young Hak Kim

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Evaluation of epidermal growth factor receptor (EGFR) as a prognostic factor for survival in non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy as first-line treatment

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.7024 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 7024-7024 ◽

Cited By ~ 2

Author(s):

M. Janas ◽

L. R. Bailey ◽

K. Schmidt ◽

N. Bindslev ◽

M. Wolf ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Platinum Based Chemotherapy ◽

Epidermal Growth ◽

Nsclc Patients ◽

First Line Treatment

Download Full-text

Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation

Lung Cancer ◽

10.1016/j.lungcan.2018.12.007 ◽

2019 ◽

Vol 128 ◽

pp. 6-12 ◽

Cited By ~ 5

Author(s):

Xiangtao Yan ◽

Huijuan Wang ◽

Peng Li ◽

Guowei Zhang ◽

Mina Zhang ◽

...

Keyword(s):

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

Egfr Tki ◽

First Line Treatment

Download Full-text